香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 WUXI XDC CAYMAN INC. （於開曼群島註冊成立的有限公司） （股份代號：2268） 藥 明 合 聯 生 物 技 術 有 限 公 司* 及 (3) 新持續關連交易 背景 茲提述(i)招股章程，內容有關（ 其中包括 ）現有持續關連交易協議；及(ii)本公司 日期為2024年4月26日、8月26日、10月9日及2025年9月2日的公告及通函，內 容有關（ 其中包括 ）2023年原材料採購服務協議、2023年抗體主服務協議及2023 年一般服務協議。 自2023年上市以來，本集團已實現顯著增長。尤其是，本集團業務於2025年上 半年繼續錄得快速強勁增長，這得益於強勁的行業利好因素及全球ADC藥物市 場 強 勁 勢 頭 的 延 續 。 於 2025 年 上 半 年 ， 本 集 團 的 收 益 及 毛 利 分 別 同 比 增 長 約 ...

Investment Rating - The report initiates coverage with a "Buy" rating for WuXi XDC [3][5][15] Core Insights - WuXi XDC is a global leader in bioconjugate drug CRDMO services, with a projected revenue CAGR of 102% from 2022 to 2024, driven by strong industry demand and capacity constraints [1][5] - The company plans to increase its capital expenditures (CAPEX) to over 7 billion RMB by 2029 to expand its production capacity, with significant investments in both domestic and international facilities [1][12] - The report highlights the rapid growth in project numbers and backlog orders, with a total of 13.29 billion USD in unfinished orders as of June 30, 2025, reflecting a year-on-year increase of 57.9% [2][12] Summary by Sections Company Overview - WuXi XDC provides comprehensive CRDMO services for bioconjugate drugs, facilitating the entire process from concept to commercialization [22] - The company has executed a total of 858 drug discovery projects since its inception, with 225 ongoing comprehensive projects as of mid-2025 [25] Market Dynamics - The ADC market is experiencing explosive growth, with ADC drugs becoming a prominent treatment modality, accounting for approximately 15.4% of FDA-approved biopharmaceuticals from 2019 to 2022 [40][42] - The global ADC market size has expanded from 2 billion USD in 2018 to 10.4 billion USD in 2023, with a projected CAGR of 38.6% [46] Financial Projections - Revenue forecasts for WuXi XDC are 60.01 billion RMB, 81.13 billion RMB, and 107.36 billion RMB for 2025, 2026, and 2027, respectively, with corresponding growth rates of 48.1%, 35.2%, and 32.3% [3][15] - The net profit estimates for the same years are 16.07 billion RMB, 21.71 billion RMB, and 29.10 billion RMB, reflecting growth rates of 50.3%, 35.1%, and 34.1% [3][15] Strategic Initiatives - The company is implementing a "global dual-plant production" strategy to enhance supply chain competitiveness, with significant investments in facilities in Shanghai, Wuxi, and Singapore [1][12] - WuXi XDC's advanced WuXiDARx™ technology aims to shorten the development cycle for ADC projects, achieving IND readiness in as little as 15 months [2][12]

港股三大指数全天水下震荡，盘中跌幅均一度扩大逾1%。截止收盘，恒生指数跌0.76%或200.96点，报 26344.14点，全日成交额为2905.37亿港元；恒生国企指数跌1.07%，报9370.73点；恒生科技指数跌 0.58%，报6257.91点。 东吴证券认为，港股仍在震荡上行趋势中，下行有底。该行指出，美联储降息靴子落地，港股上涨更取 决于产业景气度和基本面边际变化；当前外资对中国资产感兴趣的越来越多，但资金流入还处于早期阶 段；当前港股仍是结构性行情，建议自下而上寻相对低估的个股。 蓝筹股表现 中芯国际(00981)再创新高。截至收盘，涨5.16%，报73.35港元，成交额98.78亿港元，贡献恒指25.48 点。高盛近日指出，将中芯国际H股目标价上调15%至73.1港元。这一乐观预期主要源于对中国IC设计 需求和人工智能趋势的看好，预计这将强劲支撑中芯国际的产量与平均售价。该行同时上调公司2028- 2029年营收及每股收益预测，并指出2025年第三季度营收环比预计增长5%–7%，可能成为短期股价催 化剂。 4. 钢铁股表现活跃。截至收盘，马鞍山钢铁股份(00323)涨4.44%，报2.59港元； ...

华鑫证券认为，中国创新药出海是创新成果持续涌现和创新效率驱动的结果，全球新药研发向中国转 移，是不可逆转的产业趋势，虽然在短期内或出现波动，但全年增长的趋势不变。 在创新药出海热潮的强力驱动下，国内创新药板块迎来显著复苏。从中报数据来看，较多创新药企成功 实现扭亏为盈，业绩基本面的改善直接点燃了市场对创新药板块的投资热情，板块估值修复行情延续。 港股医药板块午后拉升，恒生医药ETF（159892）涨超2%，药明合联领涨，诺诚健华、药明生物、药 明康德、晶泰控股等跟涨。 2025年以来，中国创新药领域License-out交易频发。据医药魔方数据，2025年上半年，中国License-out 交易共计72笔，交易总金额较2024年全年高出16%，其中单笔金额超过10亿美元的交易达16笔，重磅交 易的落地提升了市场对创新药出海的信心。 ...

Group 1 - The Hang Seng Index fell by 0.99%, down 263 points, closing at 26,281 points, while the Hang Seng Tech Index dropped by 1.18% [1] - Apple-related stocks surged due to strong pre-order demand for new iPhone models, with companies like Q Technology rising by 9%, Sunny Optical Technology by 5.9%, and GoerTek by 10% [1] - Yihuatong's stock increased by over 16% after forming a fuel cell company with Toyota and announcing the termination of the acquisition of Xuyang Hydrogen Energy [1] - Hong Teng Precision's stock rose by over 17%, benefiting significantly from the ramp-up of rack-level AI servers [1] - Baiguoyuan Group's stock surged over 22% as it plans to raise over 300 million HKD through a placement, indicating early signs of strategic adjustment [1] - Kaisa Capital's stock increased by over 10% after a Hong Kong court rejected a winding-up petition against Kaisa Group, as the company expands its RWA business [1] - China Qinfa's stock rose by over 5% due to improved profitability in its Indonesian operations and tax rate advantages on mining license fees [1] - Cloudwise Technology's stock skyrocketed by over 100%, with a 133% increase in early trading after announcing a global strategic partnership with UBTECH [1] - WuXi AppTec's stock rose by over 6%, reaching a new high after finalizing subscription agreement matters, with WuXi Biologics' shareholding exceeding 50% [1] Group 2 - Huiju Technology's stock increased by over 11% after OpenAI partnered with Luxshare Precision to develop AI hardware, with the company being a member of the Luxshare system [2] - The demand for Chinese export container shipping has shown weakness, leading to continued adjustments in ocean freight market rates, with shipping stocks like COSCO Shipping Energy falling over 6% and Seaspan International down over 5% [2] - West Air's stock dropped by over 8% following a recent crash of the SR22T single-engine aircraft [2] Group 3 - Hong Kong Broadband's stock fell by over 4% after China Mobile Hong Kong completed a tender offer and plans to raise public shareholding ratio through a placement [3]

Group 1 - The Hang Seng Index fell by 0.99%, down 263 points, closing at 26,281 points, while the Hang Seng Tech Index dropped by 1.18% [1] - Apple-related stocks surged due to strong pre-order demand for new iPhone models, with companies like Q Technology rising by 9%, Sunny Optical Technology increasing by 5.9%, and GoerTek up by 10% [1] - Yihua Tong saw a rise of over 16% after partnering with Toyota to establish a fuel cell company, while also announcing the termination of the acquisition of Xuyang Hydrogen Energy [1] - Hong Teng Precision surged over 17%, benefiting significantly from the ramp-up of rack-level AI servers [1] - Baiguoyuan Group increased by over 22%, planning to raise over 300 million HKD through a share placement, indicating early signs of strategic adjustment effectiveness [1] Group 2 - Kaisa Capital rose by over 10% after a Hong Kong court rejected a winding-up petition against Kaisa Group, as the company expands its RWA business [2] - China Qinfa saw an increase of over 5% due to improved profitability in its Indonesian operations and tax rate advantages on mining license fees [2] - Yunzhihui Technology skyrocketed by over 100%, with a 133% increase in early trading after announcing a global strategic partnership with UBTECH [2] - WuXi AppTec rose by over 6%, reaching a new high after finalizing subscription agreement matters, with WuXi Biologics' shareholding exceeding 50% [2] - Huiju Technology increased by over 11% after OpenAI partnered with Luxshare Precision to develop AI hardware, with the company being a member of the Luxshare system [2] - The demand for Chinese export container shipping appears weak, with ocean freight market rates continuing to adjust, leading to declines in shipping stocks such as COSCO Shipping Energy, which fell over 6%, and Seaspan International, down over 5% [2] - West Air experienced a drop of over 8% following a recent crash of its SR22T single-engine aircraft [2] Group 3 - Hong Kong Broadband fell by over 4% after China Mobile Hong Kong completed a tender offer, planning to raise public shareholding ratio through a share placement [3]

Market Updates - UBTECH (09880) rose over 4% after signing a global strategic cooperation agreement with Cloud Intelligence Technology on September 21, with initial orders expected to be fulfilled [1] - Changfei Fiber Optics (06869) fell over 2% as shareholders reduced their holdings by a total of 10% in H-shares, with no significant impact on financial data from the hollow-core fiber [1] - Gold stocks mostly increased, with Lingbao Gold (03330) up over 4%, Zhaojin Mining (01818) up over 3%, China Silver Group (00815) up over 4%, and Shandong Gold (01787) up over 3%. The Federal Reserve's interest rate cut is expected to support a fluctuating upward trend in gold prices [1] - Yihuatong (02402) surged over 18% after partnering with Toyota to establish a fuel cell company and announcing the termination of the acquisition of Xuyang Hydrogen Energy [1] - WuXi AppTec (02268) increased over 6% after finalizing a subscription agreement that will raise WuXi Biologics' stake to over 50% [1] - Hong Kong Broadband (01310) dropped over 3% after announcing a share placement by its controlling shareholder, China Mobile Hong Kong, to restore public shareholding [1] - Huiju Technology (01729) rose over 10% following a strategic cooperation agreement with OpenAI to develop a revolutionary AI device for consumers [1] Shipping Sector - Shipping stocks experienced significant declines, with China Merchants Energy (01138) down over 6%, Seaspan (01308) down over 5%, Orient Overseas International (00316) down over 4%, and China Merchants Industry Holdings (01919) down over 4%. The Shanghai Shipping Exchange reported weak demand for Chinese export container transport, leading to continued adjustments in ocean freight rates [2] US Market Highlights - Pony.ai (PONY.US) increased by 18.55% as the CFO announced expectations to achieve key profit targets by early 2026 [3] - FedEx (FDX.US) rose 2.32% with projected revenue growth of up to 6% this year, exceeding analyst forecasts [3] - JD.com (JD.US) saw a 0.86% increase, with the iPhone 17 series achieving record sales within the first minute of pre-sale [3] - XPeng Motors (XPEV.US) rose 1.74%, reporting a 137% year-on-year increase in overseas deliveries from January to August [3] - ZTO Express (ZTO.US) fell 0.96%, with analysts noting a significant rebound in express delivery prices in August [3] - WeRide (WRD.US) surged 10.23% after its autonomous bus Robobus received Belgium's first federal-level L4 autonomous driving test license [3] - Tesla (TSLA.US) rose 2.21% as Baird upgraded its rating to "outperform," with expectations for significant stock price increases [4] - Apple (AAPL.US) increased by 3.20% following the successful launch of the iPhone 17 series on September 19 [4] - Quantum Song (QSG.US) rose 13.22%, with the chairman announcing a focus on the trendy toy sector [4]

Group 1 - The pharmaceutical stocks have generally risen, with notable increases in companies such as WuXi AppTec (6.82% increase), Innovent Biologics (5.72% increase), and WuXi Biologics (3.86% increase) [1] - The National Healthcare Security Administration has released the 11th batch of centralized procurement documents for drugs, emphasizing principles such as "stabilizing clinical use, ensuring quality, preventing collusion, and countering internal competition" [1] - The optimization of price control benchmarks in the procurement process indicates a shift away from simply selecting the lowest bid, reflecting a proactive approach by the healthcare authority to improve the domestic market [1] Group 2 - Guojin Securities expresses strong confidence in a reversal trend for the pharmaceutical sector in 2025, highlighting innovative drugs and the recovery of left-behind sectors as significant investment opportunities [2] - The upward trend in the innovative drug industry remains intact, with multinational corporations facing patent cliffs and likely to continue using business development strategies to fill revenue gaps [2] - Dongwu Securities notes that the easing interest rate environment is expected to enhance the prosperity of the innovative industry chain, benefiting upstream biotech and CXO sectors [2]

每经AI快讯，9月22日，港股医药股多数上扬。截至发稿，药明合联(02268.HK)涨6.82%，报75.2港元； 诺诚健华(09969.HK)涨5.72%，报17.38港元；药明生物(02269.HK)涨3.86%，报39.24港元；歌礼制药- B(01672.HK)涨3.09%，报11.01港元；恒瑞医药(01276.HK)涨2.74%，报90港元。 ...

Group 1 - The pharmaceutical stocks are mostly rising, with notable increases in companies such as WuXi AppTec (02268) up 6.82% to HKD 75.2, Innovent Biologics (09969) up 5.72% to HKD 17.38, and WuXi Biologics (02269) up 3.86% to HKD 39.24 [1] - The National Healthcare Security Administration has released the 11th batch of centralized procurement documents for drugs, emphasizing principles such as "stabilizing clinical use, ensuring quality, preventing collusion, and countering internal competition" [1] - The procurement plan optimizes the selection of price control "anchors," moving away from simply choosing the lowest bid, which reflects a proactive approach by the healthcare authority to promote a healthier domestic market [1] Group 2 - Guojin Securities expresses strong confidence in a reversal trend for the pharmaceutical sector in 2025, identifying innovative drugs and the left-side sector's recovery as the biggest investment opportunities [2] - The upward trend in the innovative drug industry remains unchanged, with multinational corporations facing patent cliffs and likely to continue using business development (BD) strategies to fill revenue gaps [2] - Dongwu Securities notes that in a context of interest rate cuts, the innovative industry chain's prosperity is expected to improve, benefiting upstream biotech and CXO sectors [2]